Fig. 3 | Scientific Reports

Fig. 3

From: Development and validation of an immune signature-based risk model for prognostic assessment in melanoma

Fig. 3

Risk model in relation to genomic heterogeneity and immune checkpoint therapy. (A) Differential distribution of tumor genomic heterogeneity markers between high-risk and low-risk groups, highlighting significant differences in Tumor Mutation Burden (TMB) and Loss of Heterozygosity (LOX). (B) Box plot of immune checkpoint-related gene expression, highlighting significantly lower PDCD1 and CD274 expression in the high-risk group. (C) Scatter plot depicting the correlation between PD-L1 gene expression and risk scores.

Back to article page